Valuation : Keros Therapeutics, Inc.

Market Cap 22Cr 19Cr 18Cr 16Cr 31Cr 2.08TCr 31Cr 210.54Cr 82Cr 1.06TCr 82Cr 81Cr 3.51TCr P/E 2026 *
-2x
P/E 2027 * -1.78x
Enterprise Value 22Cr 19Cr 18Cr 16Cr 31Cr 2.08TCr 31Cr 210.54Cr 82Cr 1.06TCr 82Cr 81Cr 3.51TCr EV / Sales 2026 *
14.1x
EV / Sales 2027 * 16x
Free-Float
46.49%
Yield 2026 *
-
Yield 2027 * -
1 day-0.09%
1 week-5.22%
Current month-0.09%
1 month+9.93%
3 months+1.56%
6 months-21.99%
Current year-45.63%
1 week 10.58
Extreme 10.58
11.48
1 month 9.69
Extreme 9.69
11.71
Current year 9.69
Extreme 9.69
20.34
1 year 9.69
Extreme 9.69
22.55
3 years 9.12
Extreme 9.12
73
5 years 9.12
Extreme 9.12
73
10 years 9.12
Extreme 9.12
88.8
Manager TitleAgeSince
Chief Executive Officer 70 01/12/2015
Director of Finance/CFO 55 03/08/2026
Chief Tech/Sci/R&D Officer 53 01/06/2019
Director TitleAgeSince
Chairman 70 01/07/2024
Director/Board Member 63 01/04/2016
Director/Board Member 50 01/03/2020
Date Insider Type Main position Quantity % Market Cap. Importance
18/08/26 Sell

Executive/Senior Manager

-3,568 0.0180%
18/08/26 Sell

General Counsel

-4,485 0.0227%
18/08/26 Sell

Chief Financial Officer

-1,224 0.0062%
Change 5-day change 1-year change 3-year change Capi.($)
-0.09%-5.22%-27.22%-69.45% 22Cr
-0.25%-4.10%+38.38%+92.61% 6.82TCr
+0.93%-0.36%+47.59%+88.33% 6.42TCr
-0.25%-1.92%-10.72%+436.70% 2.65TCr
+0.33%-10.61%+1.95%-16.27% 2.56TCr
+1.09%+0.56%+31.42%-18.48% 1.99TCr
-6.09%-12.08%+226.11%+375.00% 1.71TCr
+0.65%-5.28%-1.12%+534.90% 1.49TCr
+4.12%+0.30%+52.03%+150.18% 1.41TCr
-0.24%+5.18%+23.04%+190.97% 1.24TCr
Average +0.02%-4.05%+38.14%+176.45% 2.63TCr
Weighted average by Cap. +0.10%-3.23%+41.53%+158.32%

Financials

2026 *2027 *
Net sales 1.56Cr 1.34Cr 1.26Cr 1.15Cr 2.16Cr 147.74Cr 2.18Cr 15Cr 5.81Cr 75Cr 5.84Cr 5.72Cr 249.19Cr 1.37Cr 1.18Cr 1.11Cr 1.01Cr 1.91Cr 130.27Cr 1.92Cr 13Cr 5.12Cr 66Cr 5.15Cr 5.04Cr 219.72Cr
Net income -11Cr -9.52Cr -8.95Cr -8.16Cr -15Cr -1.05TCr -15Cr -105.86Cr -41Cr -532.77Cr -41Cr -41Cr -1.77TCr -15Cr -13Cr -12Cr -11Cr -20Cr -1.4TCr -21Cr -141.39Cr -55Cr -711.6Cr -55Cr -54Cr -2.36TCr
Net Debt - -
Logo Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Employees
92
Date Price Change Volume
01/26/01 $11.07 -0.09% 96,240
31/26/31 $11.08 +0.45% 1,79,962
28/26/28 $11.03 -1.78% 3,28,287
27/26/27 $11.23 +0.99% 1,27,576
26/26/26 $11.12 -4.79% 1,13,598
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
11.07USD
Average target price
19.83USD
Spread / Average Target
+79.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KROS Stock